You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Endogena finalises enrolment for retinitis pigmentosa trial

Endogena Therapeutics has revealed that it has completed patient enrolment for its phase 1/2a trial concerning the company’s EA-2353 candidate. The therapy has been developed to treat retinitis pigmentosa (RP).